Venous thromboembolism in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with lenalidomide: a systematic review

被引：3

作者：

Sorigue, Marc ^{[1
]}

Orna, Elisa ^{[1
]}

Sancho, Juan-Manuel ^{[1
]}

机构：

[1] Univ Autonoma Barcelona, Inst Recerca Josep Carreras, ICO Hosp Germans Trias & Pujol, Dept Hematol, Ctra Canyet S-N, Badalona 08916, Spain

来源：

LEUKEMIA & LYMPHOMA | 2018年 / 59卷 / 11期

关键词：

Lenalidomide; non-Hodgkin lymphoma; chronic lymphocytic leukemia; deep vein thrombosis; venous thromboembolism; systematic review; B-CELL LYMPHOMA; SINGLE-AGENT LENALIDOMIDE; ANTHRACYCLINE-BASED THERAPY; PHASE-II TRIAL; OPEN-LABEL; ELDERLY-PATIENTS; PLUS RITUXIMAB; INVESTIGATORS CHOICE; INITIAL TREATMENT; CLINICAL-TRIAL;

D O I：

10.1080/10428194.2018.1448085

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Lenalidomide has been associated with an increased risk of venous thromboembolism (VTE) in multiple myeloma. It is unclear whether patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) are also at such risk. We conducted a systematic review of the incidence of VTE in prospective trials of lenalidomide-treated patients with NHL or CLL. Sixty-eight unique reports were assessed for inclusion. For grade >= 3 VTE, 98 events were reported in 3043 patients (60 studies) (crude incidence: 3.22% [95% confidence interval: 2.6-3.9%]). For any grade VTE, 97 events were reported in 2244 patients (46 studies) (crude incidence: 4.32% [3.5-5.2%]). Subgroup analysis showed no difference based on histological subtype or use of prophylaxis. The study is at risk of bias, largely due to insufficient data from the individual studies. Within the limitations of this systematic review, we found a low risk of VTE in patients with NHL treated with lenalidomide.

引用

页码：2602 / 2611

页数：10

共 76 条

[1] Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: An overview of systematic reviews with meta-analyses [J].

Aguiar, Patricia Melo ;

Lima, Tacio de Mendonca ;

Braga Colleoni, Gisele Wally ;

Storpirtis, Silvia .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 113 :195-212

[2] Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma [J].

Albertsson-Lindblad, Alexandra ;

Kolstad, Arne ;

Laurell, Anna ;

Raty, Riikka ;

Gronbaek, Kirsten ;

Sundberg, Jan ;

Pedersen, Lone Bredo ;

Ralfkiaer, Elisabeth ;

Karjalainen-Lindsberg, Marja-Liisa ;

Sundstrom, Christer ;

Ehinger, Mats ;

Geisler, Christian ;

Jerkeman, Mats .

BLOOD, 2016, 128 (14) :1814-1820

[3] Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia [J].

Badoux, Xavier C. ;

Keating, Michael J. ;

Wen, Sijin ;

Wierda, William G. ;

O'Brien, Susan M. ;

Faderl, Stefan ;

Sargent, Rachel ;

Burger, Jan A. ;

Ferrajoli, Alessandra .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (05) :584-591

[4] Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia [J].

Badoux, Xavier C. ;

Keating, Michael J. ;

Wen, Sijin ;

Lee, Bang-Ning ;

Sivina, Mariela ;

Reuben, James ;

Wierda, William G. ;

O'Brien, Susan M. ;

Faderl, Stefan ;

Kornblau, Steven M. ;

Burger, Jan A. ;

Ferrajoli, Alessandra .

BLOOD, 2011, 118 (13) :3489-3498

[5] A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs [J].

Bagot, Martine ;

Hasan, Baktiar ;

Whittaker, Sean ;

Beylot-Barry, Marie ;

Knobler, Robert ;

Shah, Emad ;

Marreaud, Sandrine ;

Morris, Stephen ;

Dalle, Stephane ;

Servitje, Octavio ;

Cowan, Richard ;

Vakeva, Liisa ;

Chaby, Guillaume ;

Jonak, Constanze ;

Fox, Christopher P. ;

Ritchie, Diana ;

Vermeer, Maarten H. ;

Stadler, Rudolf ;

Ortiz Romero, Pablo L. ;

Scarisbrick, Julia ;

Quaglino, Pietro .

EUROPEAN JOURNAL OF DERMATOLOGY, 2017, 27 (03) :286-294

[6] A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL [J].

Brown, J. R. ;

Abramson, J. ;

Hochberg, E. ;

Mikler, E. ;

Dalton, V. ;

Werner, L. ;

Reynolds, H. ;

Thompson, C. ;

McDonough, S. M. ;

Kuang, Y. ;

Ritz, J. ;

Neuberg, D. ;

Freedman, A. S. .

LEUKEMIA, 2010, 24 (11) :1972-1975

[7] Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events [J].

Caruso, Vanesa ;

Di Castelnuovo, Augusto ;

Meschengieser, Susana ;

Lazzari, Maria A. ;

de Gaetano, Giovanni ;

Storti, Sergio ;

Iacoviello, Licia ;

Donati, Maria Benedetta .

BLOOD, 2010, 115 (26) :5322-5328

[8] Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial) [J].

Chanan-Khan, A. ;

Egyed, M. ;

Robak, T. ;

Martinelli de Oliveira, F. A. ;

Echeveste, M. A. ;

Dolan, S. ;

Desjardins, P. ;

Blonski, J. Z. ;

Mei, J. ;

Golany, N. ;

Zhang, J. ;

Gribben, J. G. .

LEUKEMIA, 2017, 31 (05) :1240-1243

[9] Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study [J].

Chanan-Khan, Asher ;

Miller, Kena C. ;

Musial, Laurie ;

Lawrence, David ;

Padmanabhan, Swaminathan ;

Takeshita, Kenichi ;

Porter, Carl W. ;

Goodrich, David W. ;

Bernstein, Zale P. ;

Wallace, Paul ;

Spaner, David ;

Mohr, Alice ;

Byrne, Catriona ;

Hernandez-Ilizaliturri, Francisco ;

Chrystal, Cynthia ;

Starostik, Petr ;

Czuczman, Myron S. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) :5343-5349

[10] Bendamustine plus rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: AWisconsin Oncology Network Study [J].

Chang, Julie E. ;

Havighurst, Thomas ;

Kim, KyungMann ;

Eickhoff, Jens ;

Traynor, Anne M. ;

Kirby-Slimp, Rachel ;

Volk, Lynn M. ;

Werndli, Jae ;

Go, Ronald S. ;

Weiss, Matthias ;

Blank, Jules ;

Kahl, Brad S. .

BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (02) :283-291

← 1 2 3 4 5 6 7 8 →